Navigation Links
Combination of drugs produces dramatic tumor responses in advanced melanoma patients
Date:6/2/2013

CHICAGO, JUNE 2, 2013 The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Several patients experienced tumor shrinkage of more than 80 percent within 12 weeks of receiving the drugs, and the shrinkage was long lasting. Further, 40 percent of patients who received varying concurrent dosages had an objective response meaning at least a 50 percent reduction in tumor size. Side effects from the drug combination were manageable and often reversible.

"We are very excited about the response rates these patients have experienced. This kind of deep and rapid tumor regression has never been seen in melanoma using immunotherapy, and suggests that these two drugs could be better used in combination than alone," said Jedd D. Wolchok, MD, PhD. Dr. Wolchok, a medical oncologist at the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering, is lead author on The New England Journal of Medicine paper and also presented the findings at ASCO.

Dr. Wolchok and his team combined ipilimumab and nivolumab because promising results in preclinical testing suggested the drugs impact the immune system in a complementary way. By blocking the inhibitory marker CTLA-4, ipilimumab, which the FDA approved for advanced melanoma in 2011, activates the immune system, prompting T cells to start attacking the tumor. Blocking PD-1 further activates T cells in a different manner, allowing them to continue the attack.

"Previous studies had shown that ipilimumab alone could prolong overall survival in advanced melanoma patie
'/>"/>

Contact: Caitlin Hool
hoolc@mskcc.org
646-227-3956
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Melanoma Patients Receive Promising News Regarding Cancer Immunotherapy Combination Treatment
2. Underactive Thyroid and Heart Failure a Bad Combination: Study
3. Learn How to Incorporate Ayruveda into Yoga Practices, Discover Dosha Combinations, and How to Live in Balance this Saturday, May 18th at The YogaSoul Center
4. Added benefit of saxagliptin/metformin combination is not proven
5. New drug combination therapy developed to treat leukemia
6. Some patients with incurable tumors and BRCA mutations respond to new 2-drug combination
7. Different drug combinations work best for prevention versus treatment of colorectal tumors
8. Combination therapy provides similar clinical benefit as single drug treatment in MS
9. Comparing combination therapies for advanced head and neck cancer shows no improvement
10. New drug combination could prevent head and neck cancer in high-risk patients
11. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Wohl Associates of Bohemia, NY, specialists ... taken delivery of used industrial pasta machinery from Toresani ... equipment for producing gnocchi and tortelloni. , The mixers ... La Parmigiana mixer/extruder. With a 2.2 kW (5 HP) ... is 17” wide, 28” long and 23” deep that ...
(Date:9/23/2014)... OR (PRWEB) September 23, 2014 Humans do ... their waste water as they could says leading waste water ... Grigg advocated a program in which 100% of all water ... as pure as when it was removed. Solid waste removed ... to the environment. Grigg explained his Total Water Management (TWM) ...
(Date:9/23/2014)... Rosa, CA (PRWEB) September 23, 2014 On ... the arrival of the most technically advanced horticultural LED grow ... it again with the XL750 and XL1000 ... as well as the experienced horticulturalist, because it has what ... the light spectrum. Kind LED's grower-tested 12 band spectrum (also ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 A ... and Digestive and Kidney Diseases has found ... more cases of adults and children developing kidney stones. ... 2005 - 2011 across several U.S. cities, including Dallas, ... that patients usually sought treatment for kidney stones within ...
(Date:9/23/2014)... Hope For The Warriors® is excited ... be hosted in Boston, Massachusetts on Sunday, November 9, ... signature event honors the courage of our wounded service ... Proceeds from the evening will benefit Hope For The ... of self, restoring the family unit, and restoring hope ...
Breaking Medicine News(10 mins):Health News:Used Industrial Pasta Machinery Now Available at Wohl Associates 2Health News:Leading Water Treatment Expert Calls for 100% Waste Water Recycling 2Health News:Leading Water Treatment Expert Calls for 100% Waste Water Recycling 3Health News:Kind LED K5 Series XL1000 Grow Lights Sell Out in Only 2 Days 2Health News:New Study Finds Link Between Higher Temperatures and Kidney Stones in the United States 2Health News:New Study Finds Link Between Higher Temperatures and Kidney Stones in the United States 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 3
... so many problems in our health care delivery,system and ... are having problems getting care as well as paying ... Health & Science University,family physician. The study, "Insurance Plus ... Health Care Access for Low Income,Families," recently was published ...
... in the world over 300 families are being recruited ... the treatment of childhood eczema. , The independent trial ... received funding of nearly 1million from the Department of ... Assessment (HTA) programme. The study will focus on hard ...
... a CT scan, and the masses look benign, they ... recent study conducted by researchers at Brown University in ... CT, we are frequently encountering findings that are not ... called incidentalomas, of which adrenal masses are quite common, ...
... to Evaluate Ultra-Pure Ethyl EPA-Niacin ... Treatment of Niacin- Induced Flushing, LONDON, November 29 ... has commenced a phase I clinical,safety and efficacy trial in ... and niacin on niacin induced,flushing. Flushing is a common side ...
... 29 Diabetes Response,Service, the first and only ... and Canada December 1st, 2007 providing scheduled,daily phone ... subscribers to,prevent hypoglycemia and complications such as seizures, ... provides customizable,scheduled text message reminders to help manage ...
... Nov. 29 As part of its HIV,Testing ... for,leading experts on HIV/AIDS issues including HIV screening, ... women., In September 2006, Centers for Disease ... screening that called for,voluntary opt-out screening to be ...
Cached Medicine News:Health News:New study shows low-income families face 3 barriers to health care 2Health News:New study shows low-income families face 3 barriers to health care 3Health News:Eczema sufferers test out benefits of water softeners 2Health News:Eczema sufferers test out benefits of water softeners 3Health News:Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 2Health News:Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 3Health News:Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 4Health News:Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 5Health News:Diabetes Response Service Launches in U.S. and Canada 2Health News:Experts Available to Discuss World AIDS Day, HIV/AIDS Issues Facing America 2
(Date:9/23/2014)... 2014 Enable Injections , developer of ... it easy and nearly painless for patients to self-inject ... has been named winner of the ,Buzz of BIO ... biotech sector.    Enable is one of only ... number of votes in the "Late Stage Leaders" category.  ...
(Date:9/23/2014)... Sept. 23, 2014   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... precision thermal shipping products for cells and tissues  ... to its Scientific Advisory Board.  The new members are ... , PhD. Dr. Acker is a Senior ...
(Date:9/23/2014)... LONDON , September 23, 2014 ... pharmaceutical assets, announces the appointment of Jarrod ... role, Mr Longcor is responsible for structuring, negotiating ... financial investments, as well as providing management and ... member of the Executive leadership team. ...
Breaking Medicine Technology:Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Avillion Appoints Jarrod Longcor as Chief Business Officer 2
... May 26, 2011 Rigel Pharmaceuticals, Inc. ... of its previously announced underwritten public offering of 16,300,000 ... of $8.00 per share to the public. The gross ... be approximately $130,400,000, before deducting underwriting discounts and commissions, ...
... Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP ) ... amount of senior unsecured notes. The notes will be unsecured, ... certain of the Company,s subsidiaries.   Endo intends ... cash on hand and borrowings under its new credit facility, ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3Endo Pharmaceuticals Holdings Inc. Announces Proposed Private Offering of Senior Notes 2
... ENA Multiparameter Kit is designed ... six of the most common ... unique quality control system. The ... well in each strip gives ...
Inquire...
Microalbumin Linearity Control...
The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
Medicine Products: